John C.M. Farquhar

HTFL CEO John C.M. Farquhar sold 22,562 shares at $27.75 (10b5-1 plan); stock down 36.5% from 52-week high, company unprofitable.

John C.M. Farquhar sold 22,562 shares under a pre-arranged 10b5-1 trading plan adopted on 2025-09-12, reducing his holdings by 4.9% from 457,935 to 435,373 shares at $27.75 on 2026-07-10. The sale is scheduled and non-discretionary under the 10b5-1 framework, so it reflects prior planning rather than current market judgment. Contextually, the stock has declined 36.5% from its 52-week high of $41.22 and 21.3% over the prior 30 days; Heartflow remains unprofitable with a net income of $-27,380,000 despite 39.9% annual revenue growth to $52,587,000. His prior open-market sales across tickers have averaged a 90-day return of +5.4%, suggesting past sales preceded stock appreciation, though specific outcomes at HTFL are limited due to the recency of most trades in his same-ticker history.

CEO John C.M. Farquhar sells 38,900 HTFL shares at $35.00 ($1.4M) under 10b5-1 plan; stock now -13.5% from 52-week high.

CEO John C.M. Farquhar sold 38,900 shares of Heartflow for $1,361,500 on 2026-06-24, reducing his holdings from 496,835 to 457,935 shares, a 7.8% reduction. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-12, making it scheduled rather than discretionary. At the sale price of $35.00, the stock was 13.5% below its 52-week high of $41.22, though it has gained 21.8% over the past 30 days and 44.4% over 90 days. The company itself remains unprofitable with net income of negative $27,380,000 on revenue of $52,587,000 in the latest quarter, though it is growing revenue at 39.9% annually. His prior four sales at HTFL show mixed near-term outcomes: the most recent sale on 2026-06-10 is not yet measurable; earlier sales showed a 30-day return of +10.4% and a 90-day return of +7.0% from the 2026-04-10 sale, but a 30-day decline of -24.3% from the 2026-02-10 sale.

CEO John C.M. Farquhar sold 22.6K shares of HTFL at $28.50 under pre-arranged 10b5-1 plan; stock now $33.24

John C.M. Farquhar, CEO of Heartflow Inc., sold 22,562 shares at $28.50 on 2026-06-10 under a 10b5-1 trading plan adopted on 2025-09-12, reducing his holdings from 519,397 shares to 496,835 shares. The transaction was scheduled rather than discretionary. The stock currently trades at $33.24, above the sale price, and has posted a 90-day gain of +62.2%, though the CEO's prior same-ticker sales (three trades at HTFL) showed mixed 30-day outcomes ranging from -24.3% to +10.4%. The company remains unprofitable with net income of $-27.4M on quarterly revenue of $52.6M, though it demonstrated +39.9% annual revenue growth, providing limited visibility into valuation sustainability.

CEO Farquhar sells 22,562 shares at $29.12 amid unprofitable operations and mixed prior exit timing.

CEO John Farquhar is selling shares as Heartflow faces a challenging financial backdrop — the company lost over $116 million annually with negative earnings, though revenue is growing briskly. This is the third open-market sale at Heartflow within the past three years for Farquhar, who has yet to purchase shares on the open market as CEO. Farquhar's prior two exits at this company show conflicting timing: at the 30-day mark, one sale proved well-timed (the stock fell afterward) and one was poorly timed (the stock rose); over 90 days, both prior sales were poorly timed as the stock recovered and gained. The current sale occurs as the stock trades notably below its 52-week high, having retreated from a stronger recent period. Without additional cluster context or material events disclosed in the filing itself, this appears to be a routine portfolio management move from the CEO, though the pattern of repeated selling without any offsetting purchases warrants tracking against near-term company catalysts.

CEO Farquhar sold 22,562 shares of HTFL at $26.72; stock now at $29.05 (30-day +41.8%), company unprofitable at -$50.9M net income.

CEO John C.M. Farquhar sold 22,562 shares (22.6K shares) at $26.72 on 2026-04-10, reducing his stake from 571,725 to 549,163 shares (-3.9%). The sale occurred ahead of a significant 30-day rally of +41.8%, meaning the stock price rose substantially after the transaction. Heartflow remains unprofitable with net income of -$50.9M on quarterly revenue of $46.3M, though the company shows strong annual revenue growth of +39.9%. The CEO's prior cross-ticker selling history shows an average 30-day return of -24.3%, and his prior HTFL sale on 2026-02-10 also preceded a -24.3% 30-day decline, but this current sale did not precede a similar downturn—the stock rallied instead. Investors should track whether this represents a one-time portfolio adjustment at the CEO level despite the company's growth trajectory.

Heartflow CEO Farquhar sells 22,562 shares at $27.46 under pre-arranged 10b5-1 plan

Farquhar, as Chief Executive Officer, sold 22,562 shares of Heartflow at $27.46 on 2026-02-10 for a total value of $619,552.52, reducing his holdings from 614,218 shares to 591,656 shares—a -3.7% reduction in his position. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-09-12, meaning it was scheduled in advance and not a discretionary trade decision. Since the sale is governed by a 10b5-1 plan executed on a predetermined schedule, it does not reflect contemporaneous judgment about the stock's valuation or company prospects. The CEO retains substantial holdings of 591,656 shares post-transaction.